Intrauterine ultrasound-guided transcervical radiofrequency ablation

Lambert R, Strohmaier C
Record ID 32018000624
English
Authors' objectives: Myomas of the uterus are the most common benign neoplasms in the female pelvis. In addition to the definitive removal of the uterus (hysterectomy) or uterus-preserving procedures (Myomectomy, MRgFUs, UAO, UAE, USgFUS/USgHIFU), intrauterine ultrasound-guided transcervical radiofrequency ablation (TFA) is another uterus-preserving, mostly in the outpatient setting conducted intervention for myomas. In TFA, radiofrequency energy (RF) is used to cause coagulative necrosis of the tissue to reduce the volume and associated symptoms of uterine leiomyomas.
Authors' results and conclusions: The quality of the evidence regarding efficacy and safety was rated as low or very low for all relevant endpoints.
Authors' recommendations: Inclusion in the Austrian benefit catalogue is currently not recommended. Due to the low quality of the evidence, comparative studies of TFA in symptomatic myomas are necessary in order to make a reliable statement regarding clinical efficacy and safety.
Authors' methods: No comparative studies were identified in the course of the search strategy. The study pool for the evaluation of evidence consisted of three prospective single-arm studies (234 patients), which were published in seven publications.
Details
Project Status: Completed
URL for project: https://aihta.at/page/bewertung-medizinischer-einzelleistungen-mel-2019-1/en
Year Published: 2020
URL for published report: http://eprints.aihta.at/1255/1/DSD_120.pdf
URL for additional information: http://eprints.aihta.at/1255/
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Leiomyoma
  • Myoma
  • Radiofrequency Ablation
  • Uterus
  • Uterine Neoplasms
Keywords
  • Radiofrequency ablation
  • uterine leiomyoma
  • myoma ablation
  • myoma therapy
Contact
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.